BDgene Appoints Dr. Lin Zhang as Senior Vice President
08.02 2022

On February 7, 2022, Shanghai BDgene Technology Co., Ltd. announced the appointment of Dr. Zhang Lin as Senior Vice President. Dr. Zhang will be fully responsible for the construction of BDgene's strategic level, assist the CEO to efficiently implement the company's strategy, and be responsible for pipeline strategy, new drug development and commercialization, business cooperation and other businesses, and report to the company's founder and CEO, Dr. Cai Yujia.


Dr. Lin Zhang

Dr. Zhang Lin holds a master's degree in clinical medicine from XiangYa School of Medicine, Central South University, and a doctorate in molecular biology from the University of Manchester, UK. She has worked for many years in world-renowned pharmaceutical companies and scientific research institutions. Previously, Lin Zhang held senior positions in British cell therapy companies Quell Therapeutics, Enara Bio and R&D institution OXGENE. She is familiar with team management and business cooperation, and can effectively lead the R&D team. She has extensive work experience in the field of gene and cell therapy, especially vector design. She has been responsible for several important projects, including "Tissue-specific promoter development for targeted human tissue expression by viral vectors".

Dr. Lin Zhang also served as a co-investigator at Shanghai Jiao Tong University , establish GMP-like facility for rAAV manufacturing, develop innovative gene therapy and gene editing technologies for Hemophilia and develop and optimize scalable mammalian cell culture processes for rAAV production.she has been responsible for the key projects”rAAV gene therapy for Hemophilia“、”Genome Editing Mediated Therapy of Hemophilia to Recover Hemostasis“, etc.In addition to her management experience and scientific research ability, Dr. Zhang Lin also has extensive clinical experience. She served as an attending physician in the Second XiangYa Hospital of Central South University, mainly for the diagnosis and treatment of leukemia, lymphoma and other cancers.

Dr. Yujia Cai, founder and CEO of BDgene, said:

Welcome Dr. Lin Zhang to join BDgene! Dr. Zhang has the scientific research strength of top scientists and working experience in famous pharmaceutical companies. Dr. Zhang Lin will serve as the senior vice president of BDgene and will be fully responsible for the company's strategic work. BDgene is currently in the stage of full-speed development. It is believed that the addition of Dr. Zhang will help BDgene develop rapidly, accelerate the process of projects, strengthen R&D and innovation capabilities, promote team building, and develop more innovative varieties with global First-in-Class. Accelerate the pace of BDgene's progress.

Dr. Lin Zhang said:

It is an honor to join BDgene. BDgene has an independent innovative platform-based delivery technology, and multiple new drug pipelines have demonstrated excellent clinical effects. I look forward to working with the team to actively promote product innovation and self-developed production potential, and accelerate the development and promotion of clinical product projects, so as to achieve BDgene's goal of developing innovative gene therapy products to cure more patients.

More News
More news


Building 10, No.55 Bixi Road, Minhang District, Shanghai,China